News » Dr. Adey Berhanu Publishes a Case Report on "Pegloticase failure and a...

Dr. Adey Berhanu Publishes a Case Report on "Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout."

Pegloticase is a highly effective therapy for patients with refractory and/or tophaceous gout, but has a high discontinuation rate (30-50%) due to development of anti-drug antibodies causing loss of efficacy and risk of infusion reactions.  This case report demonstrates that low doses of oral immunosuppressive therapy may provide a safe, cost-effective adjunct to prevent the development of anti-drug antibodies associated with infusion reactions and high rate of pegloticase failure in patients with refractory gout. Controlled studies to assess an immunosuppressive strategy when using pegloticase are warranted.